Pharmaceutical solutions of levosimendan
AssigneeOrion Corporation
InventorsReijo Backstrom, Paivi Granvik, Ritva Haikala, Sirpa Pelttari, Eva Saukko, Reija Yrjola
Life of this patent
Estimating the term…
Abstract
Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment of congestive heart failure.
Claims13
A pharmaceutical aqueous solution comprising levosimendan or a salt thereof as an active ingredient the pH-value of the solution being lower than 5, preferably about 4.5 or lower, and optionally a solubility enhancing agent.
Aqueous intravenous infusion solution comprising levosimendan or a salt thereof as an active ingredient the pH-value of the solution being lower than 5, preferably about 4.5 or lower, and optionally a solubility enhancing agent.
A pharmaceutical solution, particularly an intravenous infusion concentrate, comprising
- (a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient,
- (b) pharmaceutically acceptable organic solvent comprising ethanol,
- (c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from 2 to 4, and optionally
- (d) a water-solubility enhancing agent.
Dependencies are inferred from the claim text.